Boston Scientific Returns to CIIE with Innovations Driving 'Healthy Aging'

Shanghai, November 5, 2020 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) officially made its debut at the third China International Import Expo (hereinafter referred to as "CIIE"), showcasing its leadership in global minimally invasive interventional medicine and its agile innovation capabilities in response to pandemic trends. With a 300-square-meter main booth and a 54-square-meter public health and epidemic prevention zone, the company demonstrated its commitment to advancing the "Healthy China" initiative through cutting-edge medical technologies.

Boston Scientific's Main Booth at the 3rd China International Import Expo

Last year, Boston Scientific made its debut at the China International Import Expo (CIIE), achieving remarkable results by not only securing multiple letters of intent for procurement but also ushering in a new era of close collaboration with partners across various sectors. One year later, many of the signed projects have made tangible progress. For instance, Boston Scientific has continuously deepened its cooperation with the Boao Health Ecosystem, accelerating the “pilot implementation” of innovative medical devices and real-world data research, thereby speeding up the introduction of innovative products.

“Boston Scientific has deeply appreciated the unique value of the China International Import Expo (CIIE) in connecting domestic markets and resources, as well as fostering new opportunities for development. This year, we have once again participated as scheduled,” said Zhang Jun, President of Boston Scientific’s Greater China region. “On this open and collaborative platform of the CIIE, Boston Scientific will continue to embrace the ‘China Opportunity’ and co-create ‘Global Benefits.’ We are committed to introducing more globally leading innovative solutions to China and working with local partners to look forward to a brighter future for ‘Healthy China’!”

All-Star Product Portfolio Safeguarding Healthy Aging

This year, Boston Scientific participated with a “dual-booth” presence, featuring not only a larger scale and upgraded exhibits but also signing a three-year long-term participation cooperation memorandum with the China International Import Expo Bureau, thereby taking concrete actions to further deepen its “CIIE commitment.”

At its 300-square-meter main exhibition booth, Boston Scientific showcased 80 innovative solutions, primarily covering nine major areas of critical and chronic disease management. More than half of these products were pre-market launches, comprehensively demonstrating Boston Scientific’s innovation capabilities in cardiovascular and cerebrovascular health, peripheral interventions, oncology interventions, urology, and pelvic floor health.

Notably, Boston Scientific showcased six star products that have won or been nominated for the Galien Awards—often referred to as the “Nobel Prize of Medicine”—and centrally launched four new products, including two “world’s firsts” and one Gold Edison Award winner this year. These innovations span three therapeutic areas prevalent in aging populations: peripheral vascular disease, cholangiocarcinoma, and coronary artery disease. This represents Boston Scientific’s latest progress in its commitment to helping Chinese patients manage chronic diseases and supporting China’s transition toward “healthy aging.”

Flexible Innovation to Support Routine Epidemic Prevention and Control

This year, Boston Scientific made its debut at the CIIE’s newly established Public Health and Epidemic Prevention Zone, showcasing its “United with Healthcare Professionals” anti-epidemic initiatives and its flexible, innovative medical technology ecosystem.

In response to the health demands of normalized epidemic prevention and control, “contact-free” yet “highly convenient” solutions have become a major trend in medical innovation. Boston Scientific showcased its first single-use duodenoscope approved by the U.S. FDA, which effectively reduces the risk of iatrogenic infections. Innovative technologies for remote monitoring, diagnosis and treatment, follow-up, and procedural support provide significant convenience to physicians and patients during the pandemic, lower healthcare costs, and facilitate timely, targeted therapy. Leveraging the accelerated deployment of new infrastructure such as 5G networks, Boston Scientific is also rapidly advancing the use of 5G-enabled medical imaging, remote professional training, and artificial intelligence to deliver more professional, efficient, and accessible medical services. These efforts help decentralize high-quality medical resources and enhance primary healthcare capabilities. Together, these innovative products, technologies, and services—aligned with epidemic prevention needs—demonstrate Boston Scientific’s deep insight into the local market and its unwavering commitment to standing alongside healthcare professionals.

In the coming days, Boston Scientific will launch a series of partnership signings at this year’s China International Import Expo (CIIE), joining hands with partners across various sectors to accelerate the local translation of global medical innovation achievements and jointly contribute to realizing the visionary blueprint of “Healthy Aging.”

About Boston Scientific

Boston Scientific Corporation is committed to innovating for life. We are dedicated to developing innovative medical solutions that improve the lives of patients worldwide. For more than 40 years, Boston Scientific has been a leader in the global medical technology industry, offering a broad portfolio of high-performance medical solutions to meet the urgent therapeutic needs of patients and reduce healthcare costs. For more information, please visit the company’s website:www.bostonscientific.cn

About Boston Scientific Greater China

Boston Scientific established its China headquarters in Shanghai in 1997 and currently maintains branch offices in Beijing, Shanghai, Guangzhou, Chengdu, Hong Kong, and Taiwan. The company’s core business areas include interventional cardiology, structural heart disease, cardiac rhythm management and electrophysiology, endoscopic interventions, peripheral and oncology interventions, urology and pelvic health, and respiratory products. Upholding its tradition as an innovation leader, Boston Scientific is committed to becoming a patient- and physician-centric, innovative, and respected medical technology company by providing high-quality medical products and services for prevention, diagnosis, and treatment. For more information, please visit the company’s website:www.bostonscientific.cn